Ampion™ demonstrated statistically significant reduction in pain and improvement in function at 12 weeks in severe OAK patients
- Results reflect strong safety profile with no treatment related serious, material adverse events
- Ampio's current cash runway of approximately 12 months expected to provide sufficient near-term liquidity and flexibility to support existing business operations
- Ampio plans to meet with the Food and Drug Administration (FDA) to discuss the Phase III results and Biologics License Application (BLA)
https://finance.yahoo.com/news/ampio-pharmaceuticals-announces-top-line-131500254.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.